Green LifeScience Co

Green LifeScience Co Debt

The Debt of Green LifeScience Co (114450.KQ) as of Oct 21, 2026 is 5.33 B KRW. In the previous year, Debt was 4.83 B KRW — a change of 10.40% (higher).

Debt

5.33 BKRW

YoY

10.40%

Last updated:

In 2024, Green LifeScience Co's total debt was 5.33 B KRW, a 10.40% change from the 4.83 B KRW total debt recorded in the previous year.

The Green LifeScience Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
4.15 B KRW
Jan 1, 2018
5.10 B KRW
Jan 1, 2019
5.10 B KRW
Jan 1, 2020
6.24 B KRW
Jan 1, 2021
7.49 B KRW
Jan 1, 2022
6.51 B KRW
Jan 1, 2023
4.83 B KRW
Jan 1, 2024
5.33 B KRW
The Green LifeScience Co Debt history
YEARDebtYoY
5.33 BKRW+10.40%
4.83 BKRW-25.79%
6.51 BKRW-13.13%
7.49 BKRW+19.99%
6.24 BKRW+22.40%
5.10 BKRW0.00%
5.10 BKRW+23.00%
4.15 BKRW-47.12%
7.84 BKRW+16.34%
6.74 BKRW-61.18%
17.36 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Green LifeScience Co Stock analysis

What does Green LifeScience Co do? Green LifeScience Co Ltd produces and sells pharmaceutical and agricultural raw materials and intermediates, including AMZ for crop protection, TAZD as a herbicide intermediate, D003M and T003M for artificial marble additives, and PM04 as a pharmaceutical intermediate. The company distributes its products domestically and to international markets such as Japan, the United States, and Europe, where customers purchase these materials for agricultural and pharmaceutical applications. The firm also offers antibiotics as part of its product portfolio, targeting both domestic and overseas buyers seeking specialized chemical compounds. Green LifeScience Co Ltd generates revenue through the sale of its chemical products to customers in the agricultural and pharmaceutical sectors, with key markets including Japan, the United States, and European countries. The company’s product line caters to the needs of manufacturers requiring raw materials for crop protection, herbicides, and pharmaceutical production. Its domestic and international distribution channels support consistent sales across these segments, leveraging established relationships with buyers in the chemical supply chain. The company's offerings include specific chemical compounds like AMZ, TAZD, D003M, T003M, and PM04, which are sold to customers who integrate them into larger production processes. These products are used in the creation of crop protection materials, herbicides, artificial marble, and pharmaceuticals, serving both local and global markets. Antibiotics are also part of the sales mix, contributing to the firm’s revenue from chemical intermediates and raw materials. Green LifeScience Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Green LifeScience Co's Debt Structure

Green LifeScience Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Green LifeScience Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Green LifeScience Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Green LifeScience Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Green LifeScience Co stock

Debt of Green LifeScience Co is 5.33 B KRW in 2024.

Debt of Green LifeScience Co changed from 4.83 B KRW to 5.33 B KRW, representing a 10.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Green LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Green LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Green LifeScience Co

All Key Metrics — Green LifeScience Co